EP3344226A1 - Compositions cosmétiques pour éclaircir la peau - Google Patents

Compositions cosmétiques pour éclaircir la peau

Info

Publication number
EP3344226A1
EP3344226A1 EP16760031.1A EP16760031A EP3344226A1 EP 3344226 A1 EP3344226 A1 EP 3344226A1 EP 16760031 A EP16760031 A EP 16760031A EP 3344226 A1 EP3344226 A1 EP 3344226A1
Authority
EP
European Patent Office
Prior art keywords
ascorbic acid
skin
extract
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16760031.1A
Other languages
German (de)
English (en)
Inventor
Soraya Heinen
Ira Hartmann
Marianne Waldmann-Laue
Susanne Dickhof
Melanie Giesen
Kerstin Elias
Christoph Backhausen
Iris Marina Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP3344226A1 publication Critical patent/EP3344226A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions

Definitions

  • the invention is in the field of cosmetics and relates to compositions for cosmetic and topical dermatological skin lightening, which contain ascorbic acid and / or an ascorbic acid derivative and at least one specific propionic acid derivative.
  • the invention further relates to the use of the cosmetic or dermatological compositions for reducing, eliminating and / or inhibiting irregular pigmentation (age spots and / or freckles), to achieve a more even skin appearance and / or to reduce and / or inhibit the formation of the pigments lipofuscin and melanin in the skin and / or to influence all relevant steps of melanogenesis.
  • the pigmentation of the skin takes place in the melanocytes, which are found in the lowest layer of the epidermis next to the basal cells as either isolated or frequently occurring pigment-forming cells depending on the skin type.
  • the melanocytes form melanosomes in which melanin is formed. Through various chemical and / or physical influences, in particular by UV radiation, melanin is increasingly formed. This is transported via the keratinocytes into the corneocytes (horny layer) and leads to a brownish to brown-black skin color.
  • Melanin is formed as the final stage of an oxidative process in which tyrosine is converted with the participation of the enzyme tyrosinase via several intermediates to the brown to brown-black eumelanins (DHICA and DHI melanin) or with the involvement of sulfur-containing compounds to the reddish phaeomelanin.
  • DHICA and DHI melanin brown to brown-black eumelanins
  • Age spots are a sign of aging that requires special treatment. As it is not only a more intense pigmentation of the skin, but also concretely accumulations of the brownish-waxy pigment lipofuscin (also age or wear pigment), which is the end product of the oxidation of, inter alia, unsaturated fatty acids of cell membranes and proteins. The lysosomes are no longer able to completely degrade the substance. So he stays back as a stain.
  • brownish-waxy pigment lipofuscin also age or wear pigment
  • skin whitening agents which contain ascorbic acid or its physiologically tolerated derivatives or salts and 8-hexadecene-1, 16-dicarboxylic acid, sebacic acid and / or azelaic acid.
  • Document EP 21 174998A1 relates to the use of special propionic acid derivatives as an active ingredient for skin whitening or for reducing pigment spots on the skin.
  • the object of the present invention was therefore to provide cosmetic or dermatological compositions with which any unwanted pigmentation of the skin can be effectively treated.
  • the compositions should be capable of significantly inhibiting and / or reducing the formation of melanin and lipofuscin in the treated skin, on the one hand effectively combating existing skin patches and, on the other, sustaining the regeneration of pigmentations other than the natural skin color is prevented.
  • compositions of the present invention were superior to conventional skin lightening compositions in terms of improved skin hydration, less skin tension, and a smoother, younger appearance of the skin after treatment.
  • a first subject of the invention is therefore a cosmetic or dermatological composition which, based on its total weight, a. 0.001 to 15.00% by weight of ascorbic acid, an ascorbic acid salt and / or an ascorbic acid derivative, and
  • R is -H or a linear or cross-linked, saturated or unsaturated alkyl group having 1 to 20 carbon atoms.
  • compositions according to the invention contain, based on their total weight, from 0.001 to 15.00% by weight of ascorbic acid, of an ascorbic acid salt and / or of an ascorbic acid derivative.
  • compositions according to the invention which, based on their total weight, are 0.005 to 10.00% by weight, more preferably from 0.01 to 7.50% by weight, particularly preferably from 0.05 to 6.00% by weight. %, more preferably from 0.04 to 3.50 wt .-% and in particular from 0.05 to 3.00 wt .-% of at least one compound a. contain.
  • Suitable ascorbic acid salts are preferably to be understood as meaning the alkali metal salts and alkaline earth metal salts.
  • Particularly preferred salts of ascorbic acid which can be used according to the invention as skin-whitening active ingredient are sodium hydroascorbate, sodium ascorbate, potassium hydroascorbate, potassium ascorbate, ammonium ascorbate, ammonium hydroascorbate, calcium ascorbate, calcium hydroascorbate, magnesium ascorbate and magnesium hydroascorbate.
  • Suitable ascorbic acid esters for the purposes of the present invention may preferably be selected from esters of ascorbic acid with organic acids according to the following formula (I)
  • R 1 to R 4 represent the moiety -C (O) -R and the other radicals may be hydrogen; and R is a straight-chain or branched, saturated or unsaturated alk (en) yl radical having 8 to 24, preferably 10 to 20 and in particular 13 to 17 carbon atoms.
  • Very particularly preferred esters of ascorbic acid with organic acids are the following compounds: ascorbyl palmitate, ascorbyl isopalmitate, ascorbyl tetraisopalmitate, ascorbyl stearate, ascorbyl isostearate, ascorbyl oleate, and / or ascorbyl linoleate.
  • Ascorbyl tetraisopalmitate is a particularly preferred organic ascorbic acid ester.
  • suitable ascorbic acid esters for the purposes of the present invention are esters of ascorbic acid with inorganic acids, preferably with phosphoric acid or sulfuric acid.
  • ascorbyl phosphate and / or ascorbyl sulfate or the alkali metal or alkaline earth metal salts of ascorbyl phosphate and / or ascorbyl sulfate such as, for example, the compounds known under the INCI names Sodium Ascorbyl Phosphate, Magnesium Ascorbyl Phosphate, Sodium Ascorbyl Sulfate and / or Magnesium Ascorbyl Sulfate ,
  • Magnesium ascorbyl phosphate is a particularly preferred inorganic ascorbic acid ester because of its excellent stability in aqueous media.
  • ascorbic acid derivatives with glycosidically bound sugars are inventively used with particular preference.
  • the compound known under the INCI name Ascorbyl Glucoside and / or one of the physiologically tolerable salts of this compound are particularly preferred according to the invention.
  • a first preferred embodiment of the invention is characterized in that it is used as component a.
  • Ascorbic acid ascorbic acid salts, ascorbic acid glycosides, ascorbic acid glycoside salts, ascorbic acid esters of organic acids, salts of ascorbic acid esters with organic acids, ascorbic acid esters with inorganic acids and / or salts of ascorbic acid esters with inorganic acids.
  • compositions which contain ascorbic acid and / or at least one of the compounds known under the INCI names Ascorbyl Tetraisopalmitate, Magnesium Ascorbyl Phosphate and / or Ascorbyl Glucoside.
  • ascorbic acid and / or water-soluble ascorbic acid derivatives and / or salts are used in the compositions according to the invention.
  • Ascorbic acid is stable in aqueous media only for a limited period of time, therefore, for rapid and steady availability of ascorbic acid in the skin, it is particularly advantageous to use ascorbic acid and at least one water-soluble derivative of ascorbic acid in the compositions of the present invention. Due to its excellent penetrability to the skin and rapid release of ascorbic acid after penetration, the use of ascorbyl glucoside (or one of its physiologically acceptable salts) besides ascorbic acid is particularly preferred.
  • a further particularly preferred embodiment of the invention is accordingly characterized in that the cosmetic or dermatological compositions as component a. containing a mixture of ascorbic acid and ascorbyl glucosides.
  • the compositions according to the invention particularly preferably contain the mixture of ascorbic acid and ascorbyl glucoside - based on their total weight - in an amount of from 0.01 to 5.00% by weight, more preferably from 0.02 to 4.50% by weight, particularly preferably from 0.03 to 4.00% by weight, very particularly preferably from 0.04 to 3.50% by weight and in particular from 0.05 to 3.00% by weight.
  • compositions according to the invention can be further increased if they additionally have a skin-friendly and compatible with the active ingredients a. and b.
  • well combinable drug is added.
  • Another particularly preferred further skin-lightening active ingredient with very good skin tolerance is an extract of Olea Europaea, in particular an extract of the leaves of Olea Europaea, which is commercially available under the INCI name Olea europaea leaf extra et from various suppliers. proved.
  • the preparation of the extract is carried out according to known from the prior art methods preferably from the leaves of the olive tree with a mixture of water and alcohol and subsequent hydrolysis of the extract.
  • Olive leaves contain on average 60-90 mg of the polyphenol oleuropein per gram dry weight (in addition to phenols, flavonoids, organic acids and hydrocarbons), which shows a very high antioxidant activity.
  • Oleuropein also significantly reduces the cellular waste products lipofuscin, which are responsible for the development of age spots.
  • cosmetic or dermatological compositions according to the invention are characterized in that they contain, based on their total weight, from 0.01 to 5.00% by weight, preferably 0.02 to 4.00% by weight, particularly preferably 0 , 03 to 3.00 wt .-%, most preferably 0.04 to 2.00 wt .-% and in particular 0.05 to 1, 00 wt .-% of at least one known under the INCI name Olea Europaea Leaf Extract Plant extract included.
  • compositions according to the invention may be advantageous to use mixtures of ascorbic acid and / or salts and / or derivatives of ascorbic acid with an extract of Olea Europaea in the compositions according to the invention.
  • mixtures of ascorbic acid, an ascorbic acid derivative known by the INCI name Ascorbyl Glucoside and a plant extract known by the INCI name Olea europaea leaf extract are particularly preferred within this embodiment.
  • Such mixtures are commercially available, for example under the name lllumiscin ® from Rahn. lllumiscin ® can be used preferably in the present compositions.
  • the amount used is 0.10 to 8.00 wt .-%, more preferably from 0.25 to 7.00 wt .-%, particularly preferably from 0.50 to 6.00 wt .-%, most preferably from 0.75 to 5.00 wt .-% and in particular from 1, 00 to 4.00 wt .-%, each based on the total weight of the compositions.
  • compositions according to the invention contain, based on their total weight, 0.100 to 5.00% by weight of at least one compound of the following formula
  • X for -H; an alk (en) yl group having 1 to 10 carbon atoms; for an alkali metal cation or for an ammonium ion, and
  • R is -H or a linear or cross-linked, saturated or unsaturated alkyl group having 1 to 20 carbon atoms.
  • inventive compositions which - based on their total weight - 0.15 to 4.50 wt .-%, more preferably from 0.20 to 4.00 wt .-%, particularly preferably from 0.30 to 3.50 wt .-%, most preferably from 0.40 to 3.00 wt .-% and in particular from 0.50 to 2.50 wt .-% of at least one compound b. contain the aforementioned formula.
  • X is -H, a sodium, potassium or ammonium ion, or a methyl or ethyl group
  • R stands for -H or for a Ci e-alkyl group.
  • X in the aforementioned formula is particularly preferably -H or a sodium, potassium or ammonium ion, and R is a methyl, ethyl or propyl group; most preferably X is -H and R is a methyl group.
  • compositions according to the invention contain as component b. at least one compound of the abovementioned formula in which X is -H or a sodium, potassium or ammonium ion, preferably -H, and R is -H, a methyl or ethyl group, preferably a methyl group.
  • 2- (4-hydroxyphenoxy) propionic acid and its salts are commercially available in racemic form, as well as in the form of their R and S enantiomers.
  • 2- (4-hydroxyphenoxy) propionic acid and / or salts of 2- (4-hydroxyphenoxy) propionic acid may be present in the compositions according to the invention - preferably on their total weight - preferably in amounts of 0.15 to 4.50 wt .-%, more preferably from 0.20 to 4.00 wt .-%, particularly preferably from 0.30 to 3.50 wt .-%, very particularly preferably from 0.40 to 3.00 wt .-% and in particular from 0.50 to 2.50 wt .-% are used.
  • 2- (4-hydroxyphenoxy) propionic acid is understood as meaning both the racemic mixture and (S) -2- (4-hydroxyphenoxy) propionic acid or (R) -2- (4-hydroxyphenoxy) propionic acid.
  • Preferred in terms of excellent activity against pigment spots of any kind is (R) -2- (4-hydroxyphenoxy) propionic acid or a physiologically acceptable salt such as alkali or ammonium salts of (R) -2- (4-hydroxyphenoxy ) propionic acid.
  • compositions according to the invention resulted in particularly good results with regard to the lightening of pigment spots when ascorbic acid and / or its derivatives and / or salts with olive leaf extract and (R) -2- (4-hydroxyphenoxy) propionic acid was combined.
  • the content of lipofuscin in the skin could thereby be significantly reduced and thus also age spots better brightened or mitigated.
  • cosmetic or dermatological compositions according to the invention are therefore characterized in that they
  • At least one plant extract known under the INCI name Olea Europaea Leaf Extract at least one plant extract known under the INCI name Olea Europaea Leaf Extract.
  • compositions according to the invention can be further increased if they further 2-pyrrolidone-5-carboxylic acid and / or a physiologically acceptable salt and / or derivative of 2-pyrrolidone-5-carboxylic acid is added.
  • salts of 2-pyrrolidone-5-carboxylic acid can facilitate the transport of ascorbic acid and / or its water-soluble derivatives and / or salts into the skin and thus increase the availability of ascorbic acid in the skin.
  • cosmetic or dermatological compositions according to the invention are accordingly characterized in that they contain, based on their total weight, from 0.001 to 10.00% by weight of 2-pyrrolidone-5-carboxylic acid and / or a physiologically tolerated salt of 2-pyrrolidone 5-carboxylic acid.
  • alkali metal, ammonium, alkaline earth metal and / or zinc salts of 2-pyrrolidone-5-carboxylic acid have proven, such as sodium, potassium, ammonium, magnesium, calcium and / or zinc salts of 2-pyrrolidone -5-carboxylic acid.
  • Particularly suitable is the zinc salt of 2-pyrrolidone-5-carboxylic acid (ZnPCA), since it in addition to the aforementioned effect also positively influences the skin moisture and can further impart a sebumregulierenden effect the compositions of the invention.
  • compositions according to the invention which contain -0.001 to 10.00% by weight, preferably 0.002 to 7.50% by weight, particularly preferably 0.003 to 5.00% by weight, based on their total weight .-%, most preferably 0.004 to 2.50 wt .-% and in particular 0.005 to 1, 00% by weight of at least one zinc salt of 2-pyrrolidone-5-carboxylic acid (ZnPCA) included.
  • ZnPCA 2-pyrrolidone-5-carboxylic acid
  • compositions according to the invention for further support of the skin whitening action of the compositions according to the invention and / or for simultaneous care (in particular for increasing the skin moisture and elasticity of the skin) it may be advantageous if the cosmetic or dermatological further active compounds according to the invention, preferably special plant extracts and / or hyaluronic acid (derivatives) to be added.
  • Suitable plant extracts are, above all, those which can be easily incorporated into the compositions according to the invention and optimally support the lightening of the skin, but in particular the achievement of a more uniform skin tone.
  • These preferably include the extracts of Quassia amara, Pisum sativum, Bambusa vulgaris, Opuntia ficus indica and / or Brassicae.
  • Hyaluronic acid (derivatives) according to the invention is / are preferably understood to mean hyaluronic acid and / or physiologically tolerated salts and / or derivatives of hyaluronic acid.
  • cosmetic or dermatological compositions according to the invention are therefore characterized in that, based on their total weight,
  • 0.01 to 20.00 wt .-% preferably 0.05 to 17.50 wt .-%, particularly preferably 0, 10 to 15.00 wt .-%, most preferably 0.50 to 12, 50 wt .-% and in particular 0.75 to 10.00 wt .-% hyaluronic acid and / or an ester of hyaluronic acid and / or a salt of hyaluronic acid.
  • Quassia amara (Brazilian Quassia tree, Quassia tree, Bitterwood) is a species in the broom family (Simaroubaceae). It is widespread in the Neotropics.
  • the extracts which can be used according to the invention are preferably obtained from the wood.
  • Extracts from Quassia amara can according to known manufacturing processes in variable composition with solvents such. As water, methanol, ethanol. Acetone, etc., and mixtures thereof at temperatures from room temperature to 100 'C with gentle to vigorous mixing within 10 min. To 24 hr. Under atmospheric pressure up to 200 bar. For enrichment of effectiveness-determining components further concentration steps can be carried out such.
  • Bambusa vulgaris extract and / or Pisum sativum extract support the collagen and elastin synthesis in the skin and can contribute to achieving a particularly even and elastic appearance of the skin in the compositions according to the invention.
  • Bambusa vulgaris (Goldbamboo) is a plant of the grass family (Poaceae), which occurs predominantly in Southeast Asia and Africa.
  • Pisum sativum is a plant of the genus Peas (Pisum) from the legume family (Fabaceae) and is native to Asia Minor.
  • Extracts of Bambusa vulgaris and / or Pisum sativum can be prepared by known manufacturing processes in variable composition.
  • a polar solvent or a mixture of polar solvents is used to obtain the extract.
  • a protic solvent may be used which is selected from the group consisting of: water, methanol, ethanol, propanol, butanol, pentanol, cyclohexanol, diethylene glycol, HO- (CH 2) 2 OH and one of their mixtures.
  • an aprotic polar solvent which is selected, in particular, from the group consisting of: pyridine, butanone, acetone, AC 2 O, (Me 2 N) 2 CO, PhCN, CH 3 CH 2 CN, HM PA, PhNO 2 , McNO 2 , DMF, MeCN, sulfolane, DMSO, HCONH 2, NCONHMe, CHsCONHMe and one of their mixtures.
  • water or a mixture of water and an alcohol such as ethanol, propanol, isopropanol or butanol, a polyol such as butylene glycol or an ester such as ethyl acetate or a mixture of these solvents is used.
  • the mixing ratios of the above-mentioned solvents generally vary between 1: 1 and 1: 100, and preferably between 1: 1 and 1:10; for example, a mixture of 25/75 is used.
  • the extraction can be carried out by stirring and / or heating, for example between 30 and 60 ° C or by reflux of the solvent used.
  • the extraction is usually carried out at atmospheric pressure, but also an extraction under pressure can be carried out.
  • the extraction time is determined by the skilled person and depends in particular on the extraction conditions.
  • Also preferred according to the invention for some embodiments of the invention may be the use of Bambusa vulgaris extract and Pisum sativum extract.
  • Bambusa vulgaris extract and Pisum sativum extract are commercially available, for example under the trade name Derm SRC® PF from Barnet Products.
  • Opuntia ficus indica is a species of the genus Opuntia of the cactus family (Cactaceae), which is native to India. Extracts of Opuntia can be prepared according to known manufacturing processes in variable composition with solvents such. Water, methanol, ethanol, acetone, etc., and mixtures thereof at temperatures of 20 ° C to 100 ° C under mild to vigorous mixing within 10 min. To 24 hours. Under atmospheric pressure at up to 200 bar. For enrichment of efficacy-determining components, further concentration steps may be carried out, e.g. liquid-liquid distribution with e.g.
  • compositions according to the invention containing at least one wholly or partially hydrolyzed extract of Opuntia ficus indica (CAS No. 90082-21-6) are furthermore preferred embodiments of the present invention.
  • Brassica napus in particular has proved to be particularly suitable according to the invention among the Brassica plants. Extracts of Brassica napus increase the skin lightening effect of the aforementioned skin-lightening active ingredients d) and also lead to an improved skin tolerance and to a more intense and less irritating effect even under sunlight.
  • Rapeseed (Brassica napus) is a plant of the family Brassica (Brassicaceae).
  • compositions according to the invention which contain at least one wholly or partially hydrolyzed extract from fermented plant parts of Brassica napus are particularly preferred.
  • Suitable salts of hyaluronic acid are preferably their alkali metal and / or ammonium salts, for example the hyaluronic acid salt commercially available under the INCI name Sodium Hyaluronate from various suppliers (Therapo, CPN).
  • Preferred esters of hyaluronic acid may be selected from silanol esters, as obtainable, for example, under the INCI name Dimethylsilanol Hyaluronate.
  • a preferred commercial product is offered for example by the company under the name Exsymol DSH CN ® commercially.
  • hyaluronic acid in pure form, it can also be part of small beads which can be added to the compositions according to the invention. Suitable beads are available, for example under the trade name Hyaluronic Filling Spheres ® by the company BASF.
  • At least one organic UV filter is contained both in the oil phase and in the water phase.
  • the cosmetic or dermatological compositions according to the invention therefore comprise from 0.01 to 25.00% by weight of at least one UV filter, the quantities being based on the total weight of the compositions.
  • Further preferred amounts of the at least one UV filter in the compositions of the invention from 0.05 to 22.50 wt .-%, particularly preferably from 0, 10 to 20.00 wt%, most preferably from 0.50 to 17.50 wt .-% and in particular from 1, 00 to 15.00 wt .-%.
  • Preferred water-soluble organic UV filters are preferably selected from
  • benzimidazole sulfonic acid e.g. Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and its salts.
  • phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt ICI name Disodium Phenyl Dibenzimidazole Tetrasulfonate
  • Neo Heliopan AP is available from Symrise.
  • Preferred oil-soluble UV filters are selected from
  • Octocrylene 2-Cyano-3,3-phenylcinnamic acid 2-ethylhexyl ester
  • Octocrylene is preferred in a total amount of from 0.50 to 15.00 wt%, more preferably from 1.00 to 13.00 wt%, especially from 3.00 to 1100 wt%, and most preferably 5 , 00 to 10.00 wt .-%, contained in the compositions of the invention, wherein the amounts are based on the total weight of the compositions.
  • compositions according to the invention comprise 4-tert-butyl-4'-methoxydibenzoylmethane in a total amount of 0.50 to 10.00% by weight, preferably 1.00 to 8.00% by weight, particularly preferably 2.00 to 5 , 00 wt .-% and extremely preferably 3.00 to 4.00% by weight, in each case based on the total weight of the composition according to the invention,
  • 3,3,5-trimethylcyclohexyl salicylate (INCI name homosalates), e.g. B. as Neo Heliopan HMS Symrise available.
  • Preferred oil-in-water emulsions according to the invention comprise 3,3,5-trimethylcyclohexyl salicylate in a total amount of from 0.50 to 10.00% by weight, preferably from 2.00 to 9.00% by weight, more preferably 3, 00 to 8.00 wt .-%, most preferably 3.50 to 7.00 wt .-%, each based on the total weight of the composition according to the invention, and
  • compositions according to the invention comprise as UV filter at least one derivative of benzimidazole sulphonic acid and at least one further of the UV filters known under the INCI names Octocrylene and Homosalate.
  • compositions according to the invention may also be present as pastes, ointments, lotions or creams.
  • Solid funds can be present as a loose powder, pressed powder or as a pen.
  • compositions according to the invention are in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-water emulsion.
  • the compositions may also be presented in anhydrous form, such as an oil or a balm.
  • the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • compositions according to the invention are in the form of an oil-in-water emulsion.
  • Another preferred embodiment of the invention is characterized in that it is in the form of an oil-in-water emulsion.
  • Cosmetic or dermatological compositions according to the invention which are formulated as an oil-in-water emulsion, furthermore contain fats, oils, waxes and / or other fatty substances as well as water and emulsifiers in addition to the aforementioned active substances.
  • the content of the water phase in the compositions according to the invention, which are present as O / W emulsions, is preferably from 10 to 90% by weight, preferably from 15 to 85% by weight preferably from 20 to 80% by weight, more preferably from 25 to 75% by weight and in particular from 30 to 70% by weight, the amounts given being based on the total weight of the O / W emulsions.
  • water phase in the context of the invention means both water and a water-alcohol mixture.
  • the alcohol content in the compositions according to the invention which are present as O / W emulsions may preferably be from 1 to 40% by weight, more preferably from 2 to 30 and in particular from 3 to 20% by weight.
  • Suitable alcohols are preferably glycol, 1,2-propylene glycol, 1,3-propylene glycol, 2-methyl-1,3-propanediol, glycerol, 1,2-butylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, pentylene glycols , 1, 2-hexanediol, 1, 6-hexanediol, 1, 2,6-hexanetriol, 1, 2-octanediol, 1, 8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, polyethylene glycol and mixtures of the aforementioned Substances into consideration.
  • Preferred water-soluble polyethylene glycols may be selected from PEG-3, PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18 and PEG-20 and mixtures thereof, with PEG-3 to PEG-8 being particularly preferred.
  • Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose and xylose may also be preferred according to the invention.
  • compositions of the invention contain as alcohol 1, 2-propylene glycol, glycerol, 1, 3-butylene glycol, 1, 6-hexanediol, diglycerol, triglycerol, dipropylene glycol and / or tripropylene glycol.
  • the oil phase is present in the compositions of the present invention which are present as O / W emulsions, preferably at a weight fraction of 0.50-50.00 wt% of the total weight of the O / W emulsion, more preferably from 1.00. 40.00 wt%, more preferably from 1.50-30.00 wt%, and most preferably from 2.00-25.00 wt%.
  • the oil phase consists of at least 90 wt .-% of an oil component at 20 ° C liquid.
  • the emulsifier (s) is (are) counted neither the oil phase nor the water phase.
  • Cosmetic or dermatological compositions according to the invention which are formulated as an oil-in-water emulsion, preferably contain a special combination of emulsifiers, which ensure the formulation of O / W emulsions with particularly light texture and stability.
  • Particularly preferred emulsifiers include anionic emulsifiers, preferably C10-24 alkyl phosphates and nonionic emulsifiers, preferably mono- and / or diacylglycerides and / or alkyl (oligo) glycosides.
  • the cosmetic or dermatological compositions according to the invention therefore contain (based on their total weight) 0.01 to 5.00 wt .-% of at least one anionic emulsifier, preferably an anionic O / W emulsifier and in particular a Cio-C24 Akylphoshats, and
  • nonionic emulsifier preferably a nonionic O / W emulsifier and / or an alkyl (oligo) glycoside.
  • Preferred ⁇ O-24-Alkylphoshate or ⁇ -24-Alkylphoshatsalze which form as an anionic oil-in-water emulsifier a first part of the preferred O / W emulsifier system are selected from the monoesters of phosphoric acid with lauryl alcohol, tridecyl alcohol, isotridecyl alcohol, Myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmityl alcohol, isocetyl alcohol, isostearyl alcohol, stearyl alcohol, oleyl alcohol, elaidyl alcohol, linoleyl alcohol, linolenyl alcohol, nonadecyl alcohol, arachyl alcohol, gadoleyl alcohol or arachidonic alcohol, which are alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolamine or glucammonium salt as sodium, potassium, alkanolamine, trialkylammoni
  • dipotassium monocetyl phosphate is particularly preferred.
  • ⁇ -24-alkyl phosphates or ⁇ -24-alkyl phosphate salts which form a first part of the preferred O / W emulsifier system as anionic oil-in-water emulsifier are selected from the diesters of phosphoric acid with lauryl alcohol, tridecyl alcohol, isotridecyl alcohol, Myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmityl alcohol, isocetyl alcohol, isostearyl alcohol, stearyl alcohol, oleyl alcohol, elaidyl alcohol, linoleyl alcohol, linolenyl alcohol, nonadecyl alcohol, arachyl alcohol, gadoleyl alcohol or arachidonic alcohol, which are alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolamine or glucammonium salt the corresponding sodium, potassium, alkanolamine, trialkylammonium, triethanol
  • potassium dicetyl phosphate is particularly preferred.
  • compositions of the present invention present as an O / W emulsion, contain at least one salt of cetyl phosphate and / or a mixture of dipotassium monocetyl phosphate and potassium dicetyl phosphate in a total amount of from 0.01 to 3.00 wt%, more preferably from 0.025 to 2.75 wt.%, Particularly preferably from 0.05 to 2.50 wt. %, very particularly preferably from 0.075 to 2.25% by weight and in particular from 0.10 to 2.00% by weight, in each case based on the total weight of the compositions.
  • Ci4-2o mono- or diacylglycerides into consideration. These are selected from monomyristoylglyceride, monopalmitoylglyceride, monostearoylglyceride, monoarachinoylglyceride, dimyristoylglyceride, dipalmitoylglyceride, distearoylglyceride and diarachinoylglyceride and mixtures thereof. Further inventively preferred Ci4-2o mono- or Diacylglyceridmischept are glycerides cured, that is, hydrogenated, preferably fully hydrogenated, fatty acids of natural oils. Hardened (hydrolyzed) palm oil glycerides are particularly preferred according to the invention.
  • Ci4-2o mono- or diacylglycerides are preferably present in the compositions according to the invention which are present as O / W emulsions in a total amount of from 0.01 to 3.00% by weight, more preferably from 0.02 to 2.60 Wt .-%, particularly preferably from 0.03 to 2.30 wt .-%, most preferably from 0.04 to 2.00 wt% and in particular from 0.05 to 1, 70 wt .-%, respectively based on the total weight of the composition.
  • compositions according to the invention which are present as O / W emulsions preferably contain Cu 2O mono- and / or diacylglyceride mixtures, in particular hardened palm oil glycerides.
  • Corresponding O / W-emulsifier systems comprising mixtures of Dikaliummonocetylphosphat and Kaliumdicetylphosphat with hardened Palmölglyceriden, are commercially available, for example under the name Emulsiphos ® 677 660 (INCI name: Potassium Cetyl Phosphate, Hydrogenated Palm Glycerides) from the company Symrise.
  • compositions according to the invention which are present as O / W emulsion is particularly preferred.
  • the amount used is 0.05 to 5.00 wt .-%, more preferably from 0.075 to 4, 75 wt .-%, particularly preferably from 0, 10 to 4.50 wt .-%, very particularly preferably from 0, 15 to 4.25 wt .-% and in particular from 0.20 to 4.00 wt .-% , in each case based on the total weight of the compositions.
  • compositions according to the invention which are in the form of an O / W emulsion therefore preferably contain 0.05 to 5.00% by weight of at least one alkyl (oligo) glycoside of the general formula RO- [G] x in which R is a saturated alkyl radical with 12 to 24 C atoms, G stands for a sugar residue with 5 or 6 C atoms and x stands for numbers from 1 to 10.
  • R is a saturated alkyl radical with 12 to 24 C atoms
  • G stands for a sugar residue with 5 or 6 C atoms
  • x stands for numbers from 1 to 10.
  • alkyl (oligo) glycosides are derived from aldoses and / or ketoses having 5 or 6 carbon atoms, preferably glucose.
  • the radical R is particularly preferably an alkyl radical having 14, 15, 16, 17, 18, 19, 20 carbon atoms or mixtures of these alkyl radicals.
  • the radical R is a mixture of C ds-alkyl chains ("cetearyl").
  • the index number x in the general formula RO- [G] x stands for the degree of oligomerization (DP), ie for the distribution of the mono- and oligoglycosides
  • the index number x preferably has a value in the range from 1 to 6, particularly preferably in the range from 1 to 3, which may not be an integer but a fractional number which can be determined analytically Alkyl (oligo) glycosides have a DP between 1.0 to 1.5.
  • alkyl (oligo) glycosides are the compounds known commercially under the INCI names Cetyl Glucoside, Stearyl Glucoside and Cetearyl Glucoside. Especially preferred is cetearyl glucoside.
  • compositions according to the invention present as O / W emulsion contain, based on their total weight, 0.10 to 4.50% by weight, preferably 0.25 to 4.00% by weight, more preferably 0, 50 to 3.50 wt .-% and in particular 0.75 to 3.00 wt .-% of at least one alkyl (oligo) glycoside of the general formula RO- [G] x, in which R is a saturated alkyl radical having 12 to 24 C Atoms, G stands for a sugar residue with 5 or 6 C atoms and x for numbers from 1 to 10.
  • the compositions according to the invention which are present as O / W emulsions comprise at least one alkyl (oligo) glycoside compound known in the INCI name cetearyl glucoside in the abovementioned amounts.
  • a corresponding commercial product which contains compounds with the INCI name Cetearyl Glucoside is available under the name Tego Care® CG 90 from Evonik.
  • Preferred oil components which can be used in compositions according to the invention which are present as emulsions are, for example, selected from:
  • volatile silicone oils which may be cyclic, such as.
  • octamethylcyclotetrasiloxane decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane and mixtures thereof, as described for. B. contained in the commercial products DC 244, 245, 344 and 345 of Dow Coming, or linear, z.
  • hexamethyldisiloxane (L 2) octamethyltrisiloxane (L 3), decamethyltetrasiloxane (L 4), any two and three mixtures of L 2, L 3 and / or L 4, as described, for.
  • Isotridecyl isononanoate cetearyl isononanot, 2-ethylhexyl laurate.
  • 2-ethylhexyl isostearate 2-ethylhexyl cocoate
  • 2-octyl dodecyl palmitate butyloctanoic acid 2-butyloctanoate.
  • Ce-C22 fatty alcohol esters of monohydric or polyhydric C 2 -C 20 -hydroxycarboxylic acids in particular the esters of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and salicylic acid.
  • esters based on linear C12 isalkanols eg. As Ci2-Ci5-alkyl lactate, and branched in 2-position C12 alkanols, for. B.
  • Di-Ci2-Ci3- alkyl malate under the trademark Cosmacol ® by the company Nordmann, Rassmann GmbH & Co, Hamburg, relate, in particular the commercial products Cosmacol ® EMI, Cosmacol ® ESI and Cosmacol ® ETI,
  • the branched saturated or unsaturated fatty alcohols having 6 to 30 carbon atoms are also often referred to as Guerbet alcohols, as they are obtainable by the Guerbet reaction.
  • Particularly preferred alcohol oils are for example Hexyldecanol (Eutanol ® G), octyl dodecanol, and 2-ethylhexyl alcohol,
  • Blends of Guerbet alcohols and Guerbet alcohol esters e.g. B. the commercial product Cetiol ® PGL (hexyldecanol and hexyldecyl laurate), the symmetrical, asymmetrical or cyciischen esters of carbonic acid with fatty alcohols, for example glycerol carbonate, dicaprylyl carbonate (Cetiol ® CC),
  • Triglycerides of linear or branched, saturated or unsaturated, optionally hydroxylated C 8-30 fatty acids may be particularly suitable. Particularly suitable may be the use of natural oils, for example soybean oil, cottonseed oil, sunflower oil, palm oil, palm kernel oil, linseed oil, almond oil, castor oil, corn oil, olive oil, rapeseed oil, sesame oil, thistle oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil and the like. But are also synthetic triglyceride oils, in particular Capric / Caprylic triglycerides, z.
  • Dicarboxylic acid esters of linear or branched C 2 -C 1 -alkanols in particular diisopropyl adipate, di-n-butyl adipate, di (2-ethylhexyl) adipate, dioctyl adipate, diethyl / dinutyl / dioctyl sebacate, diisopropyl sebacate, dioctyl malate, dioctyl maleate, dicaprylyl maleate, diisooctyl succinate, di 2-ethylhexyl succinate and di (2-hexyldecyl) succinate.
  • Di-n-alkyl ethers having a total of 12 to 36, in particular 12 to 24 carbon atoms, for.
  • di-n-octyl ether (Cetiol ® OE)
  • di-n-hexyl-n-octyl ether di-n-octyl-n-decyl ether.
  • Particularly preferred oils are silicone oils and esters of linear or branched saturated or unsaturated fatty alcohols having 2 to 30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2 to 30 carbon atoms, especially volatile and nonvolatile silicone oils from the Dow Corning 200 Fluid series and / or Dow Corning 9041 which Esteröle laurate 2-ethylhexyl palmitate, hexyldecyl laurate, 2-ethylhexyl stearate, isopropyl myristate, isopropyl palmitate and 2-ethylhexyl and / or the benzoic acid esters of linear or branched C 22 alkanols, in particular the commercial product Finsolv ®.
  • compositions of the invention may also be preferred for some embodiments of the compositions of the invention.
  • a silicone oil and an ester oil preferably.
  • compositions according to the invention which are present as emulsions, may also contain further optional constituents which give them advantageous properties.
  • Other possible ingredients include in particular:
  • Hydrogel ® 305 from SEPPIC
  • Simulgel ® 600 Simulgel ® NS
  • Simulgel ® EG Simulgel ® EPG and Sepiplus ® 400
  • Aristoflex ® AVC by Clariant
  • Carbopol commercially available products from different vendors, such as Carbopol Ultrez ® 30, nonionic from Lubrizol, the Pemulen ® and Carbopol ® grades 954, 980, 1342 and ETD 2020 (ex Noveon and BF Goodrich)
  • Hydrogeibildner such as the commercial products Mowiol ® and Luviskol ® (BASF) and / or natural Hydrogel formers, preferably hydroxyalkylcelluloses, such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose,
  • Hydroxymethylcellulose, carboxymethylcellulose, and starch degradation products such as amylose and amylopectin, chemically and / or thermally modified starch, eg hydroxypropyl starch phosphate, dihydroxypropyldistarch phosphate, in particular the anionic starch derivatives aluminum starch octenylsuccinate (eg the commercial products Dry Flo® ), sodium starch octenylsuccinate, calcium starch octenylsuccinate, furthermore chitosan and its Derivatives, furthermore, polysaccharides which form gums or gums, such as guar gum, xanthan gum, alginates, especially sodium alginate, gum arabic, karaya gum, carrageenans, locust bean gum, linseed gums, shellac and agar-agar,
  • Vitamins, provitamins and / or vitamin precursors preferably those which are assigned to the groups A, B, F and H, and in particular vitamin E acetate, vitamin A palmitate, niacinamide, panthenol, linoleic acid, linolenic acid and / or biotin.
  • the vitamins, provitamins and / or vitamin precursors can be present in the compositions according to the invention (based on their total weight) in amounts of from 0.01 to 5.00% by weight in each case.
  • Preservatives such as, for example, benzoic acid derivatives, phenoxyethanol, octoxyglycerol, which may be present in the compositions according to the invention (based on their total weight) in amounts of from 0.01 to 2.00% by weight in each case,
  • a second object of the invention is the non-therapeutic, cosmetic use of a cosmetic or dermatological composition according to the invention for
  • compositions according to the invention applies mutatis mutandis.
  • compositions were prepared, all numerical values in the following examples, unless otherwise stated, corresponding to the amount of the respective active ingredient in percent by weight, based on the total weight of the composition:
  • Ascorbic acid ascorbyl 0,001 - 0,005 - 0,01 0,05 0,04 0,05 glucoside 15,00 10,00 7,50 6,00 3,50 3,00
  • Alk (en) yl having 1 to 10 C-atoms, alkali metal cation or ammonium ion,
  • R -H or linear or crosslinked, saturated or unsaturated C 1-20 -alkyl group
  • Ascorbic acid ascorbyl 0,001 - 0,005 - 0,01 0,05 0,04 0,05 glucoside 15,00 10,00 7,50 6,00 3,50 3,00
  • Ascorbic acid ascorbyl 0,001 - 0,005 - 0,01 0,05 0,04 0,05 glucoside 15,00 10,00 7,50 6,00 3,50 3,00
  • Hyaluronic acid esters 25.00 20.00 17.50 15.00 12.50 10.00 and / or
  • Tego Care®2 CG 90 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 lllumiscin®9 0.50 to 3.00 0.50 to 3, 00 0.50 to 3.00 0.50 to 3.00
  • Quassia amara extract 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00
  • Cetearyl alcohol 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00
  • Caprylic / Capric Triglycerides 3.00 to 7.00 3.00 to 7.00 3.00 to 7.00 3.00 to 7.00 3.00 to 7.00
  • Vitamin E acetate 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00
  • Exfolactive EL®14 1, 00 to 3,00 1, 00 to 3,00 1, 00 to 3,00
  • Hyaluronic Filling Sheres®6 0.50 to 1, 50 to 0.50 to 1, 50 to 0.50 to 1.50
  • Neo Heliopan ®17 AP 0.10 to 2.00 0.10 to 2.00 0.10 to 2:00
  • Neo Heliopan ®17 AP Disodium phenyl Dibenzimidazole Symrise

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition cosmétique ou dermatologique contenant, rapporté à son poids total, - a) 0,001 à 15,00 % en poids d'acide ascorbique, un sel de l'acide ascorbique et/ou un dérivé de l'acide ascorbique et b) 0,100 à 5,00 % en poids d'au moins un composé de formule suivante HO-(C6H4)-O-CH(R)-C(O)OX, dans laquelle - X représente -H ; un groupe alkyle/alcényle ayant 1 à 10 atomes de carbone ; pour un ion de métal alcalin ou un ion ammonium et - R représente -H ou un groupe alkyle saturé ou insaturé, linéaire ou ramifié ayant 1 à 20 atomes de carbone. Cette composition est adaptée à une utilisation cosmétique non thérapeutique pour traiter la peau, en particulier pour - atténuer, éliminer et/ou inhiber toute pigmentation irrégulière (taches de vieillesse et/ou taches de rousseur) et/ou pour - obtenir un teint uniforme et/ou pour - atténuer et/ou inhiber la formation des pigments tels que la lipofuscine et la mélanine dans la peau, pour - influer sur toutes les étapes pertinentes de la mélanogenèse parmi lesquelles l'inhibition de la tyrosinase, l'inhibition des enzymes TRP1 et TRP2 (inhibition de la conversion de la tyrosine en mélanine), l'inhibition du gène gp100 (inhibition du transfert de la mélanine par la mélanogenèse).
EP16760031.1A 2015-08-31 2016-08-29 Compositions cosmétiques pour éclaircir la peau Pending EP3344226A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015216608.2A DE102015216608A1 (de) 2015-08-31 2015-08-31 Kosmetische Zusammensetzungen zur Hautaufhellung
PCT/EP2016/070284 WO2017037002A1 (fr) 2015-08-31 2016-08-29 Compositions cosmétiques pour éclaircir la peau

Publications (1)

Publication Number Publication Date
EP3344226A1 true EP3344226A1 (fr) 2018-07-11

Family

ID=56853608

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16760031.1A Pending EP3344226A1 (fr) 2015-08-31 2016-08-29 Compositions cosmétiques pour éclaircir la peau

Country Status (3)

Country Link
EP (1) EP3344226A1 (fr)
DE (1) DE102015216608A1 (fr)
WO (1) WO2017037002A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005031482A1 (de) 2005-07-04 2007-01-18 Henkel Kgaa Hautaufhellende Zusammensetzungen mit verbesserter Wirkung
EP1842530A1 (fr) * 2006-03-23 2007-10-10 Cognis IP Management GmbH Composition cosmetique comprenant un ester d'un sucre et d'acide gras et un extrait végétale de waltheria indica ou pisum sativum pour blanchir la peau
EP1967175A1 (fr) 2007-03-06 2008-09-10 Cognis IP Management GmbH Utilisation de dérivés de l'acide sinapinique et compositions comprenant de tels dérivés
EP1967176A1 (fr) 2007-03-06 2008-09-10 Cognis IP Management GmbH Utilisation de dérivés de l'acide 4-hydroxyphénoxy-acétique
US9333152B2 (en) * 2011-11-04 2016-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
DE102012222970A1 (de) * 2012-12-12 2014-06-12 Henkel Ag & Co. Kgaa Wirkstoffkombination zur Hautaufhellung I
FR3006587B1 (fr) * 2013-06-10 2016-05-27 Oreal Composition pour corriger les dyschromies cutanees et ameliorer l'homogeneite du teint
DE102013220352A1 (de) * 2013-10-09 2015-04-09 Henkel Ag & Co. Kgaa Kosmetisches oder dermatologisches Mittel zur Aufhellung und zur Vermeidung von Auftreten der Hautflecken
CN103830153B (zh) * 2014-03-27 2015-11-18 广东伊茗药业有限公司 一种保湿化妆品及其制备方法

Also Published As

Publication number Publication date
WO2017037002A1 (fr) 2017-03-09
DE102015216608A1 (de) 2017-03-02

Similar Documents

Publication Publication Date Title
WO2005092279A1 (fr) Substance a action prebiotique pour deodorants
DE102005021805B3 (de) Kosmetisches Verfahren zur Körpermodellierung mit Sonnenschutz und Modellierungs-Set
EP2253305A2 (fr) Traitement de la peau pour affiner les pores
EP2033617B1 (fr) Crème de soin cosmétique comprenant une proteine
DE102015219712A1 (de) Verdicktes Hautpflegeprodukt
JP2011032195A (ja) 老化防止化粧料
EP1576949A1 (fr) Combinaison des lipides beurre de karité et beurre de cacao pour traiter la peau cendreuse
EP3154509B1 (fr) Compositions cosmétiques servant à éclaircir la peau
DE102014104258A1 (de) Wirkstoffkombinationen aus 4-Hydroxyacetophenon und einem oder mehreren Glycerin- und/oder Oligoglycerinester von verzweigtkettigen und/oder unverzweigtkettigen Alkancarbonsäuren, sowie kosmetische oder dermatologische Zubereitungen, diese Wirkstoffkombinationen enthaltend
CN109562136A (zh) 治疗皮肤病症或减轻皮肤病症严重性的方法
EP3383355B1 (fr) Utilisation d'additifs pour conservation efficace/effet améliorant la conservation existante d'émulsions cosmétiques
WO2017036649A1 (fr) Émulsions cosmétiques h/e pour traitement antirides
WO2017037002A1 (fr) Compositions cosmétiques pour éclaircir la peau
EP3344222A1 (fr) Émulsions huile/eau cosmétique pour éclaircissement de la peau
DE102016218952B4 (de) Kosmetische Zusammensetzung von leicht viskosen Gesichtsreinigungsprodukten mit Mizellen-Technologie
WO2017037001A1 (fr) Composition cosmétique ou dermatologique pour éclaircir la peau
EP1834631B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et des dérivés de glucose ou des ethers de glycérine
DE102015224804A1 (de) Antibakterielles pflegendes Hautkosmetikum
EP2745832B1 (fr) Produit de soin cutané pour le traitement des peaux matures
WO2017036636A1 (fr) Produit de soin épaissi pour la peau
EP3389792B1 (fr) Procede de coloration de fibres keratine
EP3236920B1 (fr) Préparation antimicrobienne comprenant des alcanes de bispyridinium, des éthers de 1- ou 2-(c1 à c24-alkyl)-glycérol et des alcane-1,2-diols
DE102019218244A1 (de) Wirkstoffkombinationen aus Ubichinol und einem oder mehreren Emulgatoren aus der Gruppe der Phosphate und Sulfate sowie kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
DE102015222074A1 (de) Wirkstoffkombination zur Hautbefeuchtung in Reinigungszubereitungen
DE102006034532A1 (de) Selbstbräunungsmittel mit (2-Hydroxyethyl)harnstoff

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230531